



## NEONATAL CASES

**V.Cossey**  
**Neonatal Intensive Care Unit**  
**UZ Leuven**

# Patient 1

- mother : primigravida, GBS+, 1 dose peni
- vacuümextraction for fetal distress
- ♂, 3.340kg, 51cm, 35cm, term
- Apgarscore: 9/9
- Iraqi, consanguinity
- bloodculture taken because of incomplete antibiotic coverage

# Day 2 : parents want to go home

- Breastfeeding, weight -10%
- Clinical exam : alert, icterus, no abnormalities
- bilirubin : 13,9 mg/dl  
Coombs negative  
→ breastfeedingjaundice
- fototherapy and feedingsupplements

# Day 3 : Subfebrilitas temp 37.9 C

- Feeding well
- Mildly lethargic, icterus, fontanel normotone, normal perfusion
- bilirubin 16 mg/dl  
CRP 3 mg/l  
leucocytosis 6.700/mm<sup>3</sup>  
neutrophils 52%  
natrium 143 mmol/l  
bloodculture (umbilicalcordblood) : sterile

# Evaluation

- dehydration/fever in context of weightloss due to suboptimal milk production and hyperbilirubinemia  
or
- infection

# Evaluation

- **dehydrationfever** in context of weightloss due to suboptimal milkproduction and hyperbilirubinemia  
or
- infection  
→ continue phototherapy and close observation

## Day 4: temp 38.5 C on bilibed

- infant in good general condition, well hydrated and circulated, somewhat irritable, still jaundice
- quid sepsis?
- sepsisscreening
  - bloodculture
  - urineculture (bag)

- leucocytes : 8.400/mm<sup>3</sup>
- neutrophils 63 % - lymphocytes 20 %
- platelets : 202.000/mm<sup>3</sup>
- CRP 10 mg/l
- bilirubin 18 mg/dl
- urine : *E. Coli* 10-100.000/ml

# Would you do a lumbar puncture ?

- A: yes
- B: no

- Cerebrospinal fluid
  - leucocytes : 3.8/ $\mu$ l – no differentiation done
  - protein: 332 mg/l
  - glucose : 73 mg/dl
- start amoxicilline en amikacin
- extra IV fluid and double fototherapy
- G-6-PD-deficiency : stop vitamin K and follow hemolysis

# Day 5-7 : persistent fever

- Feeding well (expressed milk), diarrhea
- icterus, irritable when manipulated, rhinitis, vesicle on tip of tongue, palpable liver, no spleen palpable
- bloodculture, urine (suprapubic puncture), lumbar puncture, faecesculture : negative
- leucocytes 5.100/ $\mu$ l N 32 % - L 43%  
bilirubin 6 mg/dl (unconjugated)  
CRP 50 mg/l  
AST 103 mmol/l, ALT 38 mmol/l  
 $\gamma$ GT 104 mmol/l

# What is your first diagnosis ?

- A: (para)influenza
- B: enterovirus
- C : adenovirus
- D: herpesvirus

## Further anamnesis

- Mother feels tired and was sweating at night (fever ?). She has painful nipples. Never had cold sores.
- Father has recurrent labial herpes infections, recently 2 weeks before the delivery during 3 days. Did not want to cuddle the baby.

# complementary diagnostic tests : virology

- swab oro-naso-pharynx : culture
- swab lesion tongue : culture
- faeces : culture
- new lumbar puncture for PCR

# Would you stop the antibiotics ?

- A: yes
- B: no

# Would you consider to treat with acyclovir ?

- A: yes, 3 x 15 mg/kg IV
- B : yes, 3 x 15 mg/kg per os
- C : yes, 3 x 20 mg/kg IV
- D : yes, 3 x 20 mg/kg per os
- E : no, wait for viral cultures
- F : no, wait for PCR CSF

# When to initiate acyclovir in a newborn ?

- Sepsis syndrome (incl. hypothermia), particularly if accompanied by liver dysfunction (AST) or skin vesicles
- Fever and irritability with abnormal CSF findings (mononuclear predominance) particularly when accompanied by seizures
- “Rule-out” hospitalisation 3-5 days

- HSV-infection is very rare
- AND
- Acyclovir has possible side-effects :
    - neutropenia (20%) – harmful if serious bacterial infection
    - nephrotoxicity : adequate hydration
    - resistant virus
    - pharmacokinetics in VLBW-infants ?

# clinical evolution week 2

- worsening clinical condition
- gray and pale infant, irritable, poor perfusion
- tachycardie 180/min  
tachypnoe 60-80/min
- hepatosplenomegaly

# Results virology (day 7)

## Ag-detection

### faeces

|                       |          |
|-----------------------|----------|
| Adenovirus type 40-41 | negative |
| Rotavirus             | negative |

## Culture followed by Ag-detection

### swab oro-naso-pharynx

|                    |          |
|--------------------|----------|
| Adenovirus         | negative |
| Parainfluenzavirus | negative |

## Virusisolation on celculture

|  |          |
|--|----------|
| faeces : virusisolation (entero,adeno) | negative |
| swab oro-naso-pharynx                  |          |

|                                |                                 |
|--------------------------------|---------------------------------|
| virusisolation (entero,adeno)  | negative                        |
| Virusisolation (infl,RSV,hMPV) | negative                        |
| Virusisolation (HSV)           | positive Herpes simplex, type 1 |

## Virology Serology blood

|                          |          |
|--------------------------|----------|
| Herpes simplex virus IgG | negative |
| Herpes simplex virus IgM | negative |

## Molecular test :

|                       |                 |
|-----------------------|-----------------|
| swab oro-naso-pharynx |                 |
| Influenzavirus A PCR  | negative        |
| Influenzavirus B PCR  | weakly positive |
| RSV-A PCR             | negative        |
| RSV-B PCR             | negative        |
| hMPV PCR              | negative        |


### cerebrospinal fluid

|                            |   |
|----------------------------|---|
| Herpes simplex virus 1 PCR | <i>very weakly positive for HSV1 (retest)</i> |
| Herpes simplex virus 2 PCR | negative                                      |
| Enterovirus PCR            | negative                                      |

- Increase in liverdysfunction  
maximum AST 4000 U/l
- Serum day 9 : IgM positive 1.4 OD/cutoff
- CSF day 10 : HSV-1 PCR strongly positive
- Swab nipple mother : HSV-1 positive

# Evolution

- fever for 14 days in total
- liverenzymes decrease progressively, hepatosplenomegaly↓
- clinical recovery from day 17 on
- on full enteral feeds on day 19
- total IV treatment 21 days acyclovir, 5 days IV immunoglobulins
- normal oftalmological examination
- normal neuromotor development and imaging at 3 months of age



# Response to treatment

- PCR blood
  - Day 1 : Ct 23.4
  - Day 9 : Ct 24.1
  - Day 13 : Ct 27.9
  - Day 20 : Ct 36.1

# Would you consider to continue treatment beyond 3 weeks ?

- No
- No, only if LP is repeated and CSF PCR is negative at 21 days of treatment
- Yes, oral acyclovir for 6 months

# patient 2

- first pregnancy
- CMV-primo-infection 1st trimester

IgG at 10 weeks      152 AU/mL

IgM                    3 .6 OD/cutoff

IgG avidity            low 44 %

urine                    negative

# Amniocentesis ?

- A : Not indicated because no therapy available
- B : Useful for planning of follow-up
- C : Clinical predictive value of PCR quantification of CMV DNA in amniotic fluid

- Amniocentesis discussed but refused
- First signs of fetal infection at 32 weeks
  - US : mild ventriculomegaly, periventricular hyperechogenicity
  - NMR : occipital 'pseudocyst' ventriculitis- sequel, discrete hyperintens periventricular white matter, splenomegaly
- FU at 36 wks :  
growth P42, brainsparing, no other changes

# A boy is born

- PML 37.6 wks
- BW 2440 g (P3) – L 47 cm (P25) – HC 32 cm (P3)
- Apgar 9-10
- Petechiae, splenomegaly



- Thrombocytes : 28.000/mm<sup>3</sup>
- Culture and Ag-detection : urine CMV positive
- Virology Serology serum  
IgG positive > 250 AU/mL  
IgM negative
- Molecular test blood PCR CMV DNA :  
161.560 copies/mL (5 .21 log  
copies/mL)


# Neonatal work-up

- US – MRI scan
- Hearingtest – BERA audiology
- Ophthalmologic examination

# Is a lumbar puncture necessary ?

- A : no
- B : yes
- C : yes, if no other signs of CNS-involvement

- US : supependymal cysts + germinolysis
- MRI : generalised dys/demyelinisation of white matter
- BERA : R 50 dB – L nl
- Ophtalmo : no chorioretinitis



# Would you give gancyclovir ?

- A : No, only if life-threatening infection
- B : No, because of severe side-effects in neonates
- C : Yes

## Selecting neonates with congenital CMV infection for gancyclovir therapy

- Disseminated disease (+/- CNS-involvement)
- symptomatic CNS involvement at birth, excl. threshold > 100 dB at BERA audiology

– 2 or more signs of disseminated disease

- Small for gestational age (< P3).
- Petechiae
- Hepatosplenomegaly
- Thrombocytes < 75.000/mm<sup>3</sup>.
- Alanine aminotransferase (ALT = SGPT) > 100 U/L.

## – CNS involvement :

- Clinical: microcephaly, convulsions
- Biochemical: changes in CSF
- Neuro-imaging: calcifications, multiple periventricular ypodensities (subependymal pseudocysts), cortical atrophy, ventriculomegaly, hyperechogeniciteit in de caudothalamische groeve, cystische leukomalacia, vermishypoplasia, abnormal gyration, hyperdensity of white matter (MRI). *Excluding isolated striatal vasculopathy and isolated single periventricular pseudocyst.*
- Neurosensorial: hearingloss (threshold > 35 dB); chorioretinitis

# Effect of gancyclovir on hearing in symptomatic congenital CMV disease

- only RCT (n=100; 42 FU at 6 mnd+1jr)
- gancyclovir 6 mg/kg q12 h IV 6 wk versus no treatment; < 1 month
- inclusion : evidence of CNS involvement
  - microcephaly
  - intracranial calcifications
  - abnl. CSF for age
  - chorioretinitis
  - and/or hearingdeficits

## Effect : prevention of worsening hearing

|                       | FU 6 mnths     |       | FU 1 year      |       |
|-----------------------|----------------|-------|----------------|-------|
|                       | gancyclovir    | no R/ | gancyclovir    | no R/ |
| improved hearing      | 22 %           | 17 %  | 25 %           | 0 %   |
| normal – no change    | 47 %           | 22 %  | 23 %           | 22 %  |
| same loss – no change | 31 %           | 19 %  | 31 %           | 17 %  |
| worsening hearing     | 0 %<br>p < .01 | 41 %  | 21%<br>p < .01 | 61 %  |

# Hematotoxicity during therapy

| Laboratory test | Laboratory values constituting “Significant toxicity”* |                                 | Number of patients with stated laboratory abnormality |                           | <i>P</i> value  |
|-----------------|--|---------------------------------|---|---------------------------|-----------------|
|                 |  |                                 | Ganciclovir<br>(N = 47)†                              | No treatment<br>(N = 50)‡ |                 |
| Creatinine      | <7 days old:   | ≥2.5 mg/dL                      |   |                           |                 |
|                 | 7–60 days old:   | ≥1.5 mg/dL                      | 1/44 (2%)   | 0/42 (0%)                 | 1.00            |
| ALT             | 61–90 days old:  | ≥1.2 mg/dL                      |   |                           |                 |
|                 | ≥540 IU/L (≥10X Upper limit normal)                    |                                 | 0/40 (0%)   | 0/40 (0%)                 | –               |
| Total bilirubin | Preterm infants  | Term infants                    |   |                           |                 |
|                 | 3–6 days old:  | > 25 mg/dL                      | >25 mg/dL   | 11/43 (26%)               | 7/39 (18%)      |
|                 | 7–30 days old:   | ≥36 mg/dL                       | ≥21 mg/dL   |                           |                 |
| Platelets       | 31–90 days old:  | ≥6 mg/dL                        | ≥3 mg/dL  |                           |                 |
|                 | <50,000/mm <sup>3</sup>                                |                                 | 3/45 (7%)   | 2/41 (5%)                 | 1.00            |
| ANC             | <b>Grade 3–4 ANC</b>                                   |                                 | <b>29/46 (63%)</b>                                    | <b>9/43 (21%)</b>         | <b>&lt;0.01</b> |
|                 | <b>Grade 3 ANC</b>                                     |                                 |   |                           |                 |
|                 | <b>2–7 days old:</b>                                   | <b>750–1,249/mm<sup>3</sup></b> |   |                           |                 |
|                 | <b>8–56 days old:</b>                                  | <b>500–899/mm<sup>3</sup></b>   | <b>18/46 (39%)</b>                                    | <b>8/43 (19%)</b>         |                 |
|                 | <b>57–90 days old:</b>                                 | <b>250–399/mm<sup>3</sup></b>   |   |                           |                 |
|                 | <b>Grade 4 ANC</b>                                     |                                 |   |                           |                 |
|                 | <b>2–7 days old:</b>                                   | <b>&lt;750/mm<sup>3</sup></b>   |   |                           |                 |
|                 | <b>8–56 days old:</b>                                  | <b>&lt;500/mm<sup>3</sup></b>   | <b>11/46 (24%)</b>                                    | <b>1/43 (2%)</b>          |                 |
|                 | <b>57–90 days old:</b>                                 | <b>&lt;250/mm<sup>3</sup></b>   |   |                           |                 |



# Evolution

- gancyclovir for 12 + 6 d, interrupted because of severe neutropenia
- progressive hearing deficit – diabolo for serotympanon – persistent deficit 60 dB unilateral
- mental development BSID-II-NL scale developmental age 24 months at calendar age of 29 months (OI 81). mild retardation of motoric development

# Long term outcome symptomatic congenital CMV infection

- mild to severe handicap 90-95%
- psychomotor retardation 70%
- hearing loss 58 % - bilateral 37 %
- chorioretinitis 13 % - epilepsy 11 %

# Neuro-imaging and long-term outcome




## **Long term outcome asymptomatic congenital CMV infection (90%)**

- 10-15 % sequelae
  - sensori-neuronal hearing loss (15% at 6 yrs)
  - microcephaly
  - psychomotor retardation
  - dental problems
  - chorioretinitis


→ **Do we have any predictors for risk for sequelae ?**

## The proportion of children who developed sequelae at 12 months according to the neonatal CMV blood load



Lanari, M. et al. Pediatrics 2006;117:e76-e83

## The relationship between urine (shaded bars) and PB (open bars) CMV burden and hearing loss in children with congenital CMV infection



Boppana et al, J Ped 2005;146:817-23